49.52
-0.32 (-0.64%)
| Penutupan Terdahulu | 49.84 |
| Buka | 49.89 |
| Jumlah Dagangan | 1,099,778 |
| Purata Dagangan (3B) | 975,350 |
| Modal Pasaran | 3,923,845,888 |
| Harga / Pendapatan (P/E Ke hadapan) | 5.71 |
| Harga / Jualan (P/S) | 2.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2025 |
| Margin Keuntungan | 33.56% |
| Margin Operasi (TTM) | 82.43% |
| EPS Cair (TTM) | 6.51 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 459.70% |
| Nisbah Semasa (MRQ) | 3.89 |
| Aliran Tunai Operasi (OCF TTM) | 691.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 526.00 M |
| Pulangan Atas Aset (ROA TTM) | 24.42% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | PTC Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 3.0 |
| Purata | 1.38 |
|
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.42% |
| % Dimiliki oleh Institusi | 100.98% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 112.00 (Cantor Fitzgerald, 126.17%) | Beli |
| Median | 66.50 (34.29%) | |
| Rendah | 40.00 (Citigroup, -19.23%) | Pegang |
| Purata | 65.20 (31.66%) | |
| Jumlah | 7 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 44.17 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 27 May 2025 | 74.00 (49.43%) | Beli | 45.93 |
| B of A Securities | 09 May 2025 | 68.00 (37.32%) | Beli | 44.23 |
| 11 Mar 2025 | 55.00 (11.07%) | Pegang | 52.59 | |
| Barclays | 08 May 2025 | 42.00 (-15.19%) | Pegang | 42.51 |
| Baird | 07 May 2025 | 66.00 (33.28%) | Beli | 40.76 |
| Cantor Fitzgerald | 07 May 2025 | 112.00 (126.17%) | Beli | 40.76 |
| Citigroup | 07 May 2025 | 40.00 (-19.22%) | Pegang | 40.76 |
| JP Morgan | 07 May 2025 | 67.00 (35.30%) | Beli | 40.76 |
| 31 Mar 2025 | 75.00 (51.45%) | Beli | 50.96 | |
| RBC Capital | 07 May 2025 | 58.00 (17.12%) | Beli | 40.76 |
| 22 Apr 2025 | 65.00 (31.26%) | Beli | 48.19 | |
| Morgan Stanley | 07 Mar 2025 | 70.00 (41.36%) | Beli | 52.59 |
| Scotiabank | 07 Mar 2025 | 55.00 (11.07%) | Pegang | 52.59 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 May 2025 | Pengumuman | PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results |
| 05 May 2025 | Pengumuman | PTC518 PIVOT-HD Study Achieves Primary Endpoint |
| 01 May 2025 | Pengumuman | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 25 Apr 2025 | Pengumuman | PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) |
| 24 Apr 2025 | Pengumuman | PTC Therapeutics to Participate at Upcoming Investor Conferences |
| 17 Apr 2025 | Pengumuman | PTC Therapeutics to Host Conference Call to Discuss First Quarter 2025 Financial Results |
| 28 Mar 2025 | Pengumuman | PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe |
| 28 Mar 2025 | Pengumuman | PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 20 Mar 2025 | Pengumuman | PTC Therapeutics Presents New Sepiapterin Data from Ongoing Studies |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |